Seagen Inc. and Lava Therapeutics NV have entered into an exclusive license agreement under which Seagen will work to develop, manufacture and commercialize LAVA-1223, a bispecific T-cell engager designed to target and activate Vγ9Vδ2 T cells in the presence of epidermal growth factor receptor (EGFR)-expressing solid tumors.
Scientists at Surface Oncology Inc. described data from a study that aimed to evaluate the role of IL-27, a heterodimeric cytokine that plays a role in controlling the intensity and duration of immune system responses, in cancer therapy resistance.
Following epigenetic STING (stimulator of interferon genes) derepression, inhibition of the MPS1 kinase strongly reactivated cGAS-STING signaling in mutations in both the oncogene KRAS and the tumor suppressor kinase LKB/STK11. Exploiting these findings could lead to a new therapeutic strategy to target treatment-refractory tumors with mutations in KL tumors, which have mutations in both KRAS and LKB1/STK11.
The coagulation factor XI (FXI) from the liver acts as an endocrine molecule in the heart, protecting it from heart failure. Scientists at the University of California, Los Angeles (UCLA) found that this communication between the two organs is mediated by the interaction between FXI and a heart protein. This interaction activated genes in cardiomyocytes that reduced inflammation, fibrosis and diastolic dysfunction, protecting the heart from a heart attack. That FXI participates in preventing heart failure suggests the possibility of using it as a therapeutic target.
The University of Antwerp has identified new quinazolin-4-one and thieno[2,3-d]pyrimidin-4-one HER4 (ERBB4) inhibitors reported to be useful for the treatment of heart failure, cancer, fibrosis, and metabolic and inflammatory disorders.
Genfleet Therapeutics (Shanghai) Inc. has synthesized new mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer.
RSS
